Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2387294rdf:typepubmed:Citationlld:pubmed
pubmed-article:2387294lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:2387294lifeskim:mentionsumls-concept:C0085491lld:lifeskim
pubmed-article:2387294lifeskim:mentionsumls-concept:C0314833lld:lifeskim
pubmed-article:2387294lifeskim:mentionsumls-concept:C0314835lld:lifeskim
pubmed-article:2387294lifeskim:mentionsumls-concept:C0279516lld:lifeskim
pubmed-article:2387294lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:2387294pubmed:issue6lld:pubmed
pubmed-article:2387294pubmed:dateCreated1990-9-26lld:pubmed
pubmed-article:2387294pubmed:abstractTextIn vitro testing of the activity of 15 antibacterial agents against 522 clinical isolates of Aeromonas species demonstrated some species-associated trends. Amoxicillin plus clavulanic acid was effective against approximately 45% of Aeromonas caviae and Aeromonas hydrophila, but all Aeromonas sobria isolates were resistant. Aztreonam, piperacillin and mezlocillin were highly active against all the strains of Aeromonas tested. Ticarcillin was equally effective against Aeromonas caviae and Aeromonas hydrophila, but more than 50% of Aeromonas sobria isolates were resistant. The latter species was more susceptible to cephalosporins than Aeromonas hydrophila and Aeromonas caviae. Chloramphenicol, tetracycline and trimethoprim-sulfamethoxazole were extremely active against all three Aeromonas species, likewise ofloxacin and ciprofloxacin. Aztreonam, third-generation cephalosporins, chloramphenicol and the quinolones can thus be considered for therapy of infections when Aeromonas is implicated.lld:pubmed
pubmed-article:2387294pubmed:languageenglld:pubmed
pubmed-article:2387294pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2387294pubmed:citationSubsetIMlld:pubmed
pubmed-article:2387294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2387294pubmed:statusMEDLINElld:pubmed
pubmed-article:2387294pubmed:monthJunlld:pubmed
pubmed-article:2387294pubmed:issn0934-9723lld:pubmed
pubmed-article:2387294pubmed:authorpubmed-author:MartínezRRlld:pubmed
pubmed-article:2387294pubmed:authorpubmed-author:CisternaRRlld:pubmed
pubmed-article:2387294pubmed:authorpubmed-author:RojoPPlld:pubmed
pubmed-article:2387294pubmed:authorpubmed-author:QuindósGGlld:pubmed
pubmed-article:2387294pubmed:authorpubmed-author:BurgosAAlld:pubmed
pubmed-article:2387294pubmed:issnTypePrintlld:pubmed
pubmed-article:2387294pubmed:volume9lld:pubmed
pubmed-article:2387294pubmed:ownerNLMlld:pubmed
pubmed-article:2387294pubmed:authorsCompleteYlld:pubmed
pubmed-article:2387294pubmed:pagination413-7lld:pubmed
pubmed-article:2387294pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2387294pubmed:meshHeadingpubmed-meshheading:2387294-...lld:pubmed
pubmed-article:2387294pubmed:meshHeadingpubmed-meshheading:2387294-...lld:pubmed
pubmed-article:2387294pubmed:meshHeadingpubmed-meshheading:2387294-...lld:pubmed
pubmed-article:2387294pubmed:year1990lld:pubmed
pubmed-article:2387294pubmed:articleTitleIn vitro susceptibility of Aeromonas caviae, Aeromonas hydrophila and Aeromonas sobria to fifteen antibacterial agents.lld:pubmed
pubmed-article:2387294pubmed:affiliationDepartamento de Microbiología e Immunología, Facultad de Medicína y Odontología, Universidad del País Vasco, Bilbao, Spain.lld:pubmed
pubmed-article:2387294pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2387294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2387294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2387294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2387294lld:pubmed